Stocksigma LogoStocksigma Logo

Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets

Morepen Laboratories has filed its first U.S. ANDA (No. 221758) on 25th Sep'26 with the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg)

Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets

Morepen Laboratories Ltd · Press Release · 28 Sept 2026, 2:23 pm

Morepen Laboratories Submits First U.S. ANDA for Sitagliptin Tablets Morepen Laboratories has filed its first U.S. ANDA (No. 221758) on 25th Sep'26 with the USFDA for Sitagliptin Tablets USP (25 mg, 50 mg, and 100 mg), marking a key shift into integrated finished dosage CDMO services. Sitagliptin, an oral Type 2 diabetes treatment (innovator Januvia), recorded global sales of ~$1.604 billion in '25. The drug's U.S. patent expires on 24th Nov'26, with pediatric exclusivity extending to 24th May'27. Morepen estimates approval and commercial supply within 24–36 months, subject to regulatory reviews and inspections.

Original exchange filing (PDF)

More announcements from Morepen Laboratories Ltd

All Morepen Laboratories Ltd announcements